findmyKOL
Clinical trialNCT03159585CompletedPhase 1Interventional

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

SponsorZhujiang HospitalEnrollment6Bladder Carcinoma Stage IVBone and Soft Tissue TumorsBreast Cancer Stage IVEsophageal Cancer, Stage IVGastric Cancer Stage IVLiver Cancer Stage IV+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Zhujiang Hospital of Southern Mediacl University

    Guangzhou, Guangdong, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Apr 2017
Primary completion
4 Jun 2019
Completion
4 Jun 2019
Last update posted
22 Jan 2020
Registered enrollment
6
Registry id
NCT03159585

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.